Liquidia and Pharmosa Biopharm Team up to develop inhaled treprostinil

Liquidia Corporation and Pharmosa Biopharm have updated their exclusive licensing agreement for L606, an inhaled, sustained-release treprostinil formulation. The drug is currently in a clinical trial for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

The revised deal enlarges Liquidia's authorized region to include important markets in Europe, Japan, and other areas, in addition to North America. Pharmosa will keep control of specific regions such as China, Korea, Taiwan, the Middle East, North Africa, Turkey, and Southeast Asia.

Liquidia has also acquired specific privileges for utilizing Pharmosa's next-gen smart-tech nebulizers with its own liposomal drug formulations. In contrast to existing nebulized therapies for PAH and PH-ILD, these compact, light, nearly silent nebulizers offer the convenience of a dry-powder inhaler and quickly administer medication with breath-activated intelligent technology that adjusts to the patient's natural breathing rhythm.

Dr. Rajeev Saggar, chief medical officer of Liquidia, stated: “This is a great example of our approach to research and development in pulmonary hypertension. This partnership has the potential to be transformational for people living with PAH and PH-ILD, as it will combine Liquidia’s expertise as a leader in the field of pulmonary hypertension with Pharmosa’s deep experience in inhaled liposomal formulations. We are delighted by the interest from the global medical and patient communities, many of which lack access to inhaled formulations of treprostinil, as we prepare to initiate the L606 pivotal study in PH-ILD later this year. We are also encouraged by the recent scientific advice from the European Medicines Agency that supports our plan to proceed with the study as designed.”